+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England



Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England



Bmj Open 7(10): E017186



Through the National Health Service (NHS) Bowel Cancer Screening Programme (BCSP), men and women in England aged between 60 and 74 years are invited for colorectal cancer (CRC) screening every 2 years using the guaiac faecal occult blood test (gFOBT). The aim of this analysis was to estimate the cost-utility of the faecal immunochemical test for haemoglobin (FIT) compared with gFOBT for a cohort beginning screening aged 60 years at a range of FIT positivity thresholds. We constructed a cohort-based Markov state transition model of CRC disease progression and screening. Screening uptake, detection, adverse event, mortality and cost data were taken from BCSP data and national sources, including a recent large pilot study of FIT screening in the BCSP. Our results suggest that FIT is cost-effective compared with gFOBT at all thresholds, resulting in cost savings and quality-adjusted life years (QALYs) gained over a lifetime time horizon. FIT was cost-saving (p<0.001) and resulted in QALY gains of 0.014 (95% CI 0.012 to 0.017) at the base case threshold of 180 µg Hb/g faeces. Greater health gains and cost savings were achieved as the FIT threshold was decreased due to savings in cancer management costs. However, at lower thresholds, FIT was also associated with more colonoscopies (increasing from 32 additional colonoscopies per 1000 people invited for screening for FIT 180 µg Hb/g faeces to 421 additional colonoscopies per 1000 people invited for screening for FIT 20 µg Hb/g faeces over a 40-year time horizon). Parameter uncertainty had limited impact on the conclusions. This is the first published economic analysis of FIT screening in England using data directly comparing FIT with gFOBT in the NHS BSCP. These results for a cohort starting screening aged 60 years suggest that FIT is highly cost-effective at all thresholds considered. Further modelling is needed to estimate economic outcomes for screening across all age cohorts simultaneously.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059560890

Download citation: RISBibTeXText

PMID: 29079605

DOI: 10.1136/bmjopen-2017-017186


Related references

Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. European Journal of Cancer 46(11): 2059-2066, 2010

Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test. Journal of Medical Screening 18(3): 135-141, 2011

M1013 a Cost-Effectiveness Analysis in Colorectal Cancer Screening Comparing Immunochemical Faecal Occult Blood Tests with Guaiac Faecal Occult Blood Tests and No Screening. Gastroenterology 136(5): A-331, 2009

Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet. Oncology 7(2): 127-131, 2006

Piloting the Impact of Three Interventions on Guaiac Faecal Occult Blood Test Uptake within the NHS Bowel Cancer Screening Programme. Biomed Research International 2015: 928251, 2015

Experience with a wipe guaiac-based faecal occult blood test as an alternative test in a bowel screening programme. Journal of Medical Screening 17(4): 211-213, 2010

PWE-091Monitoring faecal occult blood test positivity in the NHS bowel cancer screening programme. Gut 61(Suppl 2): A334.2-A334, 2012

PTH-006Effectof Medication use on Faecal Occult Blood Test Positivity in the NHS Bowel Cancer Screening Programme. Gut 62(Suppl 1): A214.2-A214, 2013

A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Alimentary Pharmacology & Therapeutics 18(9): 941-946, 2003

Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Alimentary Pharmacology and Therapeutics 31(3): 432-439, 2010

Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing. Journal of Medical Screening 4(3): 142-146, 1997

Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut 64(8): 1327-1337, 2015

Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test. Journal of Medical Screening 26(2): 76-83, 2019

Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community. Australian and new Zealand Journal of Public Health 29(4): 358-364, 2005

Mo1954 Cost-Effectiveness of Organized Programs for Colorectal Cancer Screening: Sigmoidoscopy and Immunochemical Faecal Occult Blood Test. Gastroenterology 148(4): S-749, 2015